Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Tokyo, Japan.
J Infect Chemother. 2010 Feb;16(1):62-3. doi: 10.1007/s10156-009-0006-3.
The Centers for Disease Control and Prevention in the United States recommend the use of neuraminidase inhibitors for treating the novel influenza A (H1N1) in patients requiring desirable antiviral agents. However, the efficacy and side effects of neuraminidase inhibitors in Japanese patients infected with the novel influenza A (H1N1) are not well known. It is worth reporting on the results of the administration of neuraminidase inhibitors in Japanese patients infected with the novel influenza A (H1N1), as it is believed the number of Japanese patients will increase in the future. We treated seven Japanese patients (five adults and two juveniles) infected with the novel influenza A (H1N1) with oseltamivir and zanamivir, and good clinical courses were obtained. Our study indicates that oseltamivir and zanamivir may indeed be useful in Japanese patients infected with the novel influenza A (H1N1) in cases where antiviral therapy is required.
美国疾病控制与预防中心建议在需要理想抗病毒药物的患者中使用神经氨酸酶抑制剂治疗新型甲型流感（H1N1）。然而，神经氨酸酶抑制剂在感染新型甲型流感（H1N1）的日本患者中的疗效和副作用尚不清楚。值得报告的是，新型甲型流感（H1N1）感染的日本患者使用神经氨酸酶抑制剂的结果，因为未来日本患者的数量预计会增加。我们用奥司他韦和扎那米韦治疗了 7 名感染新型甲型流感（H1N1）的日本患者（5 名成人和 2 名青少年），并获得了良好的临床效果。我们的研究表明，在需要抗病毒治疗的情况下，奥司他韦和扎那米韦对感染新型甲型流感（H1N1）的日本患者可能确实有用。
